Premium
An Apoferritin‐based Drug Delivery System for the Tyrosine Kinase Inhibitor Gefitinib
Author(s) -
Kuruppu Anchala I.,
Zhang Lei,
Collins Hilary,
Turyanska Lyudmila,
Thomas Neil R.,
Bradshaw Tracey D.
Publication year - 2015
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.201500389
Subject(s) - gefitinib , tyrosine kinase inhibitor , drug , pharmacology , drug delivery , tyrosine kinase , chemistry , cancer research , medicine , cancer , epidermal growth factor receptor , biochemistry , signal transduction , receptor , organic chemistry
Anticancer drug Gefitinib encapsulated within human heavy chain apoferritin by diffusion allows pH‐controlled sustained release of cargo. The combination of increased cellular uptake, and potent and enhanced antitumor activity against the HER2 overexpressing SKBR3 cell line compared to Gefitinib alone, makes it a promising carrier for delivery of drugs to tumor sites.